Trade Mark Journal No.2024/040 4 October 2024
WO0000001810489 (5)
Office of origin: United States of America
Date of International Registration:2 July 2024
Date of designation in the UK:
2 July 2024

The mark consists of four overlapping circle designs.
International priority date claimed: 6 June 2024
(United States of America)
(98588346)
- Class 5
- Pharmaceuticals for use in the treatment of oncological, cardiological, dermatological, neurological, genetic, orthopedic and metabolic diseases and disorders.
Bridgebio Pharma, Inc.
Representative: Jessica L. Rothstein Goodwin Procter LLP, 620 Eighth Avenue, New York NY 10018, UNITED STATES OF AMERICA